CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Aims to Support Mental Health, Develop Improved Treatments Using Psilocybin Mushrooms

April 9, 2020 10:37:43

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human-optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, offers a timely line of organic, non-GMO and vegan-certified products. In 2019, Johns Hopkins launched a center for psychedelic research backed by private funders ( A recent article discussing the company reads, “The focus of John Hopkin’s studies will be on the affect psychedelics have on behavior, brain function, learning and memory, and the brain’s biology and mood. New therapies and the effectiveness of psilocybin are being explored for opioid addiction, Alzheimer’s disease, post-traumatic stress, post-treatment Lyme disease syndrome, anorexia nervosa and alcohol use related to depression. . . . The use of mushrooms in the health industry is growing in credibility in both scientific and financial sectors, and laws around the use of psilocybin mushrooms and their derivatives are changing. This progress is providing companies such as SHRM the opportunity to support mental health and develop new and improved treatments. The opportunities aren’t only medicinal, so while Champignon is preparing large-scale production for clinical settings, the company is also focused on retail opportunities in the health and wellness market.”

To view the full article, visit

About Champignon Brands Inc.

Champignon Brands is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol-use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, Champignon is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or standalone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
905.674.5977 Office